Bausch Health (BHC)

Executive Summary

Bausch Health Companies Inc. is a multinational specialty pharmaceutical and medical device company headquartered in Laval, Quebec, Canada. The company has undergone significant restructuring from its predecessor Valeant Pharmaceuticals and now focuses on gastroenterology, dermatology, aesthetics, and international pharmaceuticals. Bausch Health's diversified portfolio includes commercial-stage assets such as Xifaxan (rifaximin) for irritable bowel syndrome with diarrhea and hepatic encephalopathy, and its dermatology pipeline includes a Phase 1 combination gel for acne (clindamycin/adapalene/BPO) with expected completion in late 2026. The company continues to manage a substantial debt load and navigate patent litigation challenges, particularly surrounding Xifaxan. Despite these headwinds, Bausch Health has demonstrated resilience through lifecycle management and strategic partnerships, positioning itself for gradual recovery and growth. Key drivers for the company include potential patent settlements, debt reduction initiatives, and new product launches in core therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Xifaxan Patent Litigation Resolution50% success
• Q4 2026Debt Reduction Milestone Achievement70% success
• Q1 2027Acne Combination Gel Phase 1 Data Readout40% success